This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Simons, A. L. Articles by Spitz, D. R. Search for Related Content PubMed PubMed Citation Articles by Simons, A. L. Articles by Spitz, D. R.

2-Deoxy-D-Glucose Combined with Cisplatin Enhances Cytotoxicity via Metabolic Oxidative Stress in Human Head and Neck Cancer Cells

¹ Free Radical and Radiation Biology Program, Department of Radiation Oncology, Holden Comprehensive Cancer Center, The University of Iowa, Iowa City, Iowa and ² Department of Radiography, Allied Health Sciences Faculty, The Hashemite University, Al-Zarqa, Jordan

Requests for reprints: Douglas R. Spitz, Free Radical and Radiation Biology Program, Department of Radiation Oncology, B180 Medical Laboratories, University of Iowa, Iowa City, IA 52242. Phone: 319-335-8019; Fax: 319-335-8039; E-mail: douglas-spitz{at}uiowa.edu.

Glucose deprivation has been hypothesized to cause cytotoxicity by inducing metabolic oxidative stress in human cancer cells. The current work tests the hypothesis that 2-deoxy-D-glucose (2DG) combined with cisplatin [cis-diamminedichloroplatinum(II)] can enhance cytotoxicity in human head and neck cancer cells (FaDu) by mechanisms involving oxidative stress. Exposure of FaDu cells to the combination of 2DG and cisplatin resulted in a significant decrease in cell survival when compared with 2DG or cisplatin alone. Treatment with 2DG and cisplatin also caused perturbations in parameters indicative of oxidative stress, including decreased intracellular total glutathione and increased percentage of glutathione disulfide. Simultaneous treatment with the thiol antioxidant N-acetylcysteine (NAC) inhibited parameters indicative of oxidative stress, as well as protected FaDu cells from the cytotoxic effects of cisplatin alone and the combination of 2DG and cisplatin. In addition, polyethylene glycol–conjugated antioxidant enzymes (PEG-superoxide dismutase and PEG-catalase) also protected FaDu cells from 2DG toxicity. An inhibitor of glutathione synthesis, L-buthionine-[S,R]-sulfoximine (BSO), sensitized FaDu cells to the cytotoxic effects of 2DG and cisplatin, and these effects were inhibited by NAC. Furthermore, the combination of 2DG, cisplatin, and BSO significantly increased the percentage of glutathione disulfide, which was also inhibited by NAC. These results support the hypothesis that exposure of human head and neck cancer cells to 2DG combined with cisplatin enhances cytotoxicity via metabolic oxidative stress. These findings provide a strong biochemical rationale for evaluating inhibitors of glucose and hydroperoxide metabolism in combination with cisplatin for the treatment of head and neck cancer. [Cancer Res 2007;67(7):3364–70]

This article has been cited by other articles:

				H. Wu, H. Zhu, D. X. Liu, T.-K. Niu, X. Ren, R. Patel, W. N. Hait, and J.-M. Yang Silencing of Elongation Factor-2 Kinase Potentiates the Effect of 2-Deoxy-D-Glucose against Human Glioma Cells through Blunting of Autophagy Cancer Res., March 15, 2009; 69(6): 2453 - 2460. [Abstract] [Full Text] [PDF]

				L. J. Inge, K. D. Coon, M. A. Smith, and R. M. Bremner Expression of LKB1 tumor suppressor in non-small cell lung cancer determines sensitivity to 2-deoxyglucose. J. Thorac. Cardiovasc. Surg., March 1, 2009; 137(3): 580 - 586. [Abstract] [Full Text] [PDF]

				E. Hulleman, K. M. Kazemier, A. Holleman, D. J. VanderWeele, C. M. Rudin, M. J. C. Broekhuis, W. E. Evans, R. Pieters, and M. L. Den Boer Inhibition of glycolysis modulates prednisolone resistance in acute lymphoblastic leukemia cells Blood, February 26, 2009; 113(9): 2014 - 2021. [Abstract] [Full Text] [PDF]

				M. V. Mishra, K. S. Bisht, L. Sun, K. Muldoon-Jacobs, R. Awwad, A. Kaushal, P. Nguyen, L. Huang, J. D. Pennington, S. Markovina, et al. DNMT1 as a Molecular Target in a Multimodality-Resistant Phenotype in Tumor Cells Mol. Cancer Res., February 1, 2008; 6(2): 243 - 249. [Abstract] [Full Text] [PDF]